Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19

 Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19

Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19

Shots:

  • The companies collaborated to initiate a P-III trial to evaluate the safety & efficacy of INO-4800 (2.0mg, two-dose regimen, given at a gap of 1 mos.) in healthy men & non-pregnant women aged ≥18yrs. with COVID 19 across Latin American & Asia. The study expected to commence in summer across the globe
  • The 1EPs of the trial will be virologically confirmed COVID-19 disease. The P-II data showed that the therapy was well-tolerated & immunogenic in all tested age groups
  • Under the expanded collaboration, Advaccine get rights to additional Asian countries outside of Greater China

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Inovio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post